[HTML][HTML] Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer
BT Li, EF Smit, Y Goto, K Nakagawa… - … England Journal of …, 2022 - Mass Medical Soc
Background Human epidermal growth factor receptor 2 (HER2)–targeted therapies have
not been approved for patients with non–small-cell lung cancer (NSCLC). The efficacy and …
not been approved for patients with non–small-cell lung cancer (NSCLC). The efficacy and …
[HTML][HTML] First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
…, TM Bauer, F de Marinis, E Felip, Y Goto… - … England Journal of …, 2020 - Mass Medical Soc
Background Lorlatinib, a third-generation inhibitor of anaplastic lymphoma kinase (ALK),
has antitumor activity in previously treated patients with ALK-positive non–small-cell lung …
has antitumor activity in previously treated patients with ALK-positive non–small-cell lung …
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled …
…, T Takahashi, T Kumagai, K Hotta, Y Goto… - The Lancet …, 2019 - thelancet.com
Background Dual blockade of the EGFR and VEGF pathways in EGFR-mutated metastatic
non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the …
non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the …
2Mb spin-transfer torque RAM (SPRAM) with bit-by-bit bidirectional current write and parallelizing-direction current read
A 1.8V 2Mb spin-transfer torque RAM chip using a 0.2 μm logic process with an MgO
tunneling barrier cell demonstrates the circuit technologies for potential low-power non-volatile …
tunneling barrier cell demonstrates the circuit technologies for potential low-power non-volatile …
Therapeutic Potential of Afatinib in NRG1 Fusion‐Driven Solid Tumors: A Case Series
…, SV Liu, M Duruisseaux, E Branden, Y Goto… - The …, 2021 - academic.oup.com
Background Neuregulin 1 (NRG1) fusions, which activate ErbB signaling, are rare oncogenic
drivers in multiple tumor types. Afatinib is a pan‐ErbB family inhibitor that may be an …
drivers in multiple tumor types. Afatinib is a pan‐ErbB family inhibitor that may be an …
Efficient hydrogen production using cyclohexane and decalin by pulse-spray mode reactor with Pt catalysts
…, A Fukuoka, T Utagawa, M Sakuramoto, Y Goto… - Applied Catalysis A …, 2003 - Elsevier
Highly efficient production of hydrogen without CO 2 emission is achieved in the dehydrogenation
of cyclic hydrocarbons under a non-steady spray pulse operation over supported Pt …
of cyclic hydrocarbons under a non-steady spray pulse operation over supported Pt …
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3 …
…, G Liu, J Mazieres, F de Marinis, Y Goto… - The Lancet …, 2023 - thelancet.com
Background After a median follow-up of 18·3 months, the third-generation anaplastic lymphoma
kinase (ALK) tyrosine-kinase inhibitor, lorlatinib, improved progression-free survival in …
kinase (ALK) tyrosine-kinase inhibitor, lorlatinib, improved progression-free survival in …
2 Mb SPRAM (SPin-transfer torque RAM) with bit-by-bit bi-directional current write and parallelizing-direction current read
A 1.8 V 2 Mb SPin-transfer torque RAM (SPRAM) chip using a 0.2 mum logic process with
an MgO tunneling barrier cell demonstrates the circuit technologies for potential low-power …
an MgO tunneling barrier cell demonstrates the circuit technologies for potential low-power …
HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC
HA Yu, JCH Yang, H Hayashi, Y Goto, E Felip… - Future …, 2023 - Future Medicine
Limited treatment options exist for EGFR-mutated NSCLC that has progressed after EGFR
TKI and platinum-based chemotherapy. HER3 is highly expressed in EGFR-mutated NSCLC, …
TKI and platinum-based chemotherapy. HER3 is highly expressed in EGFR-mutated NSCLC, …
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01.
EF Smit, K Nakagawa, M Nagasaka, E Felip, Y Goto… - 2020 - ascopubs.org
9504 Background: T-DXd is an antibody-drug conjugate composed of an anti-HER2 antibody,
cleavable tetrapeptide-based linker, and topoisomerase I inhibitor payload. In a phase I …
cleavable tetrapeptide-based linker, and topoisomerase I inhibitor payload. In a phase I …